Tampa, FL – According to filings with the U.S. Securities and Exchange Commission, ProtoLytic is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Sweet played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ProtoLytic
ProtoLytic is driven by a core engine that correlates diagnosis with associated medical procedures, products, and drugs. The core engine algorithms use existing evidence-based guidelines to create a probability distribution for each diagnosis code and patient. ProtoLytics algorithms rely on industry-standard data to determine the relationship between different diagnosis codes and other data about the patient to form a unique decision support Plan. For example, the Plan created for a patient with osteoporosis who suffers a broken leg and weighs 300 pounds will be very different from the Treatment Plan for a 120 pound patient with a broken leg with no other medical conditions. The multi-faceted ProtoLytic system can serve both as an embedded part of a bill review or claims platform without the need for a stand-alone interface, or the client can use the system by accessing the ProtoLytic Client Portal.

To learn more about ProtoLytic, visit http://www.protolytic.com/

Contact:
Thomas Sweet, Chief Executive Officer
813-625-7227
tsweet@protolytic.com
https://www.linkedin.com/in/tom-sweet-03b16114b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved